Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

ESMO Open(2020)10.1136/esmoopen-2020-001079Source: DataRank Database

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial is a research paper published in ESMO Open (2020). On theSindex it has a DataRank of 6.4. It has been cited 524 times, with 100 citing works in its 1-hop citation network.

N/A

6.4DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access524 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02231749

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)OA: goldTopics (28)Linked Datasets (14)DataCite Reuse (14)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 15%Citation Network 85%

Base Score Contribution

0.940

From this paper's citation signal

Citation Network Contribution

5.5

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment
Nature Medicine202129 citations12 referencesContributes 0.283
Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma
JAMA Oncology202260 citations16 referencesContributes 0.257
Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
Therapeutic Advances in Urology202119 citations12 referencesContributes 0.250
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer
Clinical Lung Cancer202143 citations16 referencesContributes 0.237
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials
European Journal of Cancer2021102 citations23 referencesContributes 0.202

Authors (20)

Nizar M. Tannir ORCID,Mauricio Burotto ORCID,David F. McDermott ORCID,Elizabeth R. Plimack ORCID,Philippe Barthélémy ORCID

Live enrichment

PubMed:33246931 PMC:PMC7703447

Memorial Sloan-Kettering Cancer Center

Grant: P30 CA008748

National Institutes of Health

Grant: P30 CA016672

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

Bristol Myers Squibb

Influential Citations

goldLicense: cc-by-nc-nd

GOLDhttps://esmoopen.bmj.com/content/esmoopen/5/6/e001079.full.pdf

publisherhttps://esmoopen.bmj.com/content/esmoopen/5/6/e001079.full.pdf

publisherhttps://api.elsevier.com/content/article/PII:S2059702920327642?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2059702920327642?httpAccept=text/plain

publisherhttps://syndication.highwire.org/content/doi/10.1136/esmoopen-2020-001079

Fields of Study

Medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansCarcinoma, Renal CellKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsFollow-Up StudiesIpilimumabSunitinibNivolumab

Keywords

Long-term follow-upAdvanced Renal Cell CarcinomaCheckmate 214Nivolumab Plus IpilimumabDual Checkpoint Inhibition610Neoplasms. Tumors. Oncology. Including cancer and carcinogensIpilimumabKidney NeoplasmsNivolumabAntineoplastic Combined Chemotherapy ProtocolsSunitinibHumansCarcinoma, Renal CellRC254-282Original ResearchFollow-Up Studies

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA)

10.6084/m9.figshare.23916874.v1figshare

Additional file 1 of ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA)

10.6084/m9.figshare.23916874figshare

Additional file 1 of A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR)

10.6084/m9.figshare.25132119figshare

Additional file 1 of A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR)

10.6084/m9.figshare.25132119.v1figshare

Additional file 1 of Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapy

10.6084/m9.figshare.25309972.v1figshare

Additional file 1 of Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapy

10.6084/m9.figshare.25309972figshare

Additional file 1 of FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity

10.6084/m9.figshare.19126397figshare

Additional file 4 of FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity

10.6084/m9.figshare.19126406figshare

Additional file 2 of FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity

10.6084/m9.figshare.19126400.v1figshare

Additional file 4 of FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity

10.6084/m9.figshare.19126406.v1figshare

Additional file 2 of FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity

10.6084/m9.figshare.19126400figshare

Additional file 3 of FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity

10.6084/m9.figshare.19126403figshare

Additional file 3 of FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity

10.6084/m9.figshare.19126403.v1figshare

Additional file 1 of FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity

10.6084/m9.figshare.19126397.v1figshare